These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9688082)

  • 1. Transient dissociation between infectious HIV-1 titer and viral RNA during the early phase of AZT treatment.
    Zöllner B; Stellbrink HJ; Feucht HH; Schröter M; Baumgartner EM; Laufs R
    Microbiol Immunol; 1998; 42(6):471-3. PubMed ID: 9688082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA.
    Schüpbach J; Böni J; Flepp M; Tomasik Z; Joller H; Opravil M
    J Med Virol; 2001 Oct; 65(2):225-32. PubMed ID: 11536227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
    Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma.
    Böni J; Opravil M; Tomasik Z; Rothen M; Bisset L; Grob PJ; Lüthy R; Schüpbach J
    AIDS; 1997 May; 11(6):F47-52. PubMed ID: 9143600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.
    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C; Colimon R; Cartier F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):243-8. PubMed ID: 7788423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission.
    Jackson JB
    Pediatr AIDS HIV Infect; 1995 Dec; 6(6):358-9. PubMed ID: 11361462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of HIV-1 viral load in pregnancy.
    Lillo FB; Bucceri AM; Bettini P; Farma E; Boeri E; Mastrorilli E; Rossi G; Vignali M; Varnier OE
    AIDS; 1997 Sep; 11(11):1397-8. PubMed ID: 9302452
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.
    Prado JG; Shintani A; Bofill M; Clotet B; Ruiz L; Martinez-Picado J
    J Clin Microbiol; 2004 Apr; 42(4):1620-5. PubMed ID: 15071015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals.
    Ribas SG; Ondoa P; Schüpbach J; van der Groen G; Fransen K
    J Virol Methods; 2003 Oct; 113(1):29-34. PubMed ID: 14500124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.
    Ved Brat SS; Shepherd LP; Boulberhane A; Pierce PF; Hellman KB
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1271-81. PubMed ID: 1520539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
    Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
    N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
    Fiscus SA; Hughes MD; Lathey JL; Pi T; Jackson B; Rasheed S; Elbeik T; Reichman R; Japour A; Byington R; Scott W; Griffith BP; Katzenstein DA; Hammer SM
    J Infect Dis; 1998 Mar; 177(3):625-33. PubMed ID: 9498441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1-infected patients.
    Ercoli L; Sarmati L; el-Sawaf G; Cochi S; Lanti T; Iudicone P; Guglielmetti M; Giannini G; Galluzzo C; Tomino C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1203-7. PubMed ID: 8573376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring viral load in the clinical setting.
    Harrigan R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S34-40. PubMed ID: 8595506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
    Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo MF; Vella S
    AIDS Res Hum Retroviruses; 1997 May; 13(7):555-61. PubMed ID: 9135873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
    Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS
    Lancet; 1995 Apr; 345(8953):820-4. PubMed ID: 7534858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.